

**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims**

1. - 18. (Cancelled)

19. (Currently Amended) An immunogenic composition comprising:

(a) an antigen that ~~comprises~~consists of a truncated gp160 protein that (1) is truncated at the C-terminal end such that the truncated gp160 protein has a molecular mass of about 140 kDa, and (2) comprises the endogenous hydrophobic amino acid sequence set forth at positions 523-551 of SEQ ID NO:1;

(b) proteosomes, wherein the proteosomes are complexed or coupled with the antigen; and

(c) bioadhesive nanoemulsions,

wherein the composition ~~is formulated for intranasal or respiratory administration, wherein the composition elicits neutralizing antibodies to HIV in a subject upon administration of the composition to the subject, and wherein which the neutralizing antibodies are present in one or more of vaginal secretions, intestinal secretions, lung secretions, and feces, and wherein the composition elicits IgA and IgG antibodies that specifically bind to the truncated gp160 protein and that are present in vaginal secretions, intestinal secretions, lung secretions, and feces.~~

20. (Cancelled)

21. (Previously Presented) The immunogenic composition according to claim 19 wherein the antigen is admixed with the proteosomes to form a proteosome/antigen complex, which complex is then combined with the bioadhesive nanoemulsions.

22. (Previously Presented) The immunogenic composition according to claim 21 wherein admixing is performed in the presence of a detergent, followed by removal of the detergent by dialysis.

23. (Previously Presented) The immunogenic composition according to claim 21 wherein admixing is performed by lyophilization.

24. – 25. (Cancelled)

26. (Previously Presented) The immunogenic composition according to claim 19 wherein the truncated gp160 protein is a truncated gp160 oligomer.

27. (Currently Amended) The immunogenic composition according to claim 19 wherein the amino acid sequence of the truncated gp160 protein consists essentially of the amino acid sequence set forth at residues 33-681 of SEQ ID NO:1.

28. (Previously Presented) The immunogenic composition according to claim 19 wherein the truncated gp160 protein is recombinantly produced.

29. (Cancelled)

30. (Previously Presented) The immunogenic composition according to claim 19 wherein the proteosomes are hydrophobic, multimolecular membrane proteins.

31. – 34. (Cancelled)

35. (Previously Presented) The immunogenic composition according to claim 19 wherein the immunogenic composition is in a dosage form suitable for multiple inoculations.